4AB Stock Chart & Stats
€227.80
€1.30(0.57%)
At close: 4:00 PM EDT
€227.80
€1.30(0.57%)
Day’s Range― - ―
52-Week Range€162.85 - €234.40
Previous CloseN/A
Volume529.00
Average Volume (3M)580.00
Market Cap
€384.44B
Enterprise Value€509.95K
Total Cash (Recent Filing)€6.57B
Total Debt (Recent Filing)€70.82B
Price to Earnings (P/E)70.7
Beta0.26
Next Earnings
Oct 23, 2026EPS Estimate
3.35Next Dividend Ex-DateN/A
Dividend Yield2.65%
Share Statistics
EPS (TTM)3.55
Shares Outstanding1,766,792,800
10 Day Avg. Volume293
30 Day Avg. Volume580
Financial Highlights & Ratios
PEG Ratio-77.13
Price to Book (P/B)-124.40
Price to Sales (P/S)6.65
P/FCF Ratio22.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€238.86Price Target Upside4.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)12.15
Revenue Forecast (FY)€58.43B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationAbbVie’s very large and recurring free cash flow, roughly matching reported earnings, provides a durable funding base for R&D, dividends, share repurchases and M&A. High-quality cash conversion reduces reliance on external equity and supports multi-year strategic investments and capital return capacity.
High Margins & EfficiencySustained high gross and operating margins reflect strong pricing power, a favorable product mix and scalable commercial structure. These durable economics improve cash conversion, fund pipeline investment and provide cushion for integration costs or pricing pressure in specific markets over the medium term.
Leading Immunology GrowthRapid, broad-based immunology growth demonstrates durable market share gains and deep commercial traction across psoriasis, IBD and related indications. A dominant immunology franchise materially diversifies revenue away from legacy declines and supports long-term growth and scale benefits across development and commercialization.
Bears Say
High Leverage & Negative EquityA very large debt load and negative equity materially reduce financial flexibility, increase sensitivity to interest rates and constrain capital-allocation choices. Sustained deleveraging requires continued strong cash flow generation and limits the company’s ability to absorb large shocks or opportunistic investments without raising incremental debt.
Acquisition Financing BurdenFinancing the Apogee purchase with near-term note issuance increases interest expense and extends leverage timing, creating multi-year repayment and coverage pressures. Management’s 2x net leverage target implies reliance on uninterrupted high cash flows; any slowdown would lengthen deleveraging and intensify refinancing risk.
Legacy Product DeclinesSteep declines in established products like HUMIRA show ongoing erosion from biosimilars and competition, forcing heavy reliance on newer brands. If newer launches or pipeline advances underperform or face competitive setbacks, revenue and margin pressure could persist as legacy tailwinds vanish.
AbbVie News
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €162.85 and its highest was €234.40 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is €384.44B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Oct 23, 2026 which is in 76 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jul 31, 2026. The company reported €3.166 earnings per share for the quarter, beating the consensus estimate of €3.127 by €0.039.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €1.499 which represents an annual dividend yield of 2.65%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 3.35.
How many shares outstanding does AbbVie have?
AbbVie has 1,766,792,800 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €3.166 in its last earnings report, beating expectations of €3.127. Following the earnings report the stock price went down -1.031%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in DE:4AB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€238.86 (4.86% Upside)
€238.86 (4.86% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 86%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.12%
12-Months-Change
Fundamentals
Return on Equity
2.65%
Trailing 12-Months
Asset Growth
0.22%
Trailing 12-Months
Company Description
AbbVie
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
4AB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum: above‑consensus results, double‑digit growth across key franchises (notably SKYRIZI and RINVOQ), multiple regulatory approvals, raised guidance, and a broadened pipeline via the Apogee deal. These positives are tempered by expected declines in legacy products (HUMIRA, IMBRUVICA), modest softness in some aesthetics lines, acquisition‑related dilution and IPR&D expense, and higher interest costs and FX headwinds. On balance the company presented durable growth drivers and ample financial flexibility despite near‑term dilution and known legacy declines.View all DE:4AB earnings summaries4AB Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
4AB Stock 12 Month Forecast
Average Price Target
€238.86
▲(4.86% Upside)